Profile
| Metric | Value |
|---|---|
| Full Name | Zevra Therapeutics, Inc. |
| Ticker | NASDAQ: ZVRA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | zevra.com |
| Employees | 59 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $8.34 | |
| Price, 1D Change | -6.92% | |
| Market Cap | $470M | |
| - | ||
| PE Ratio | 13.22 | |
| Beta | 0.65 | |
| Revenue | $24M | |
| Revenue, 1Y Change | -14.02% | |
| EPS | -$2.28 | |
| EPS, 1Y Change | -75.63% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:16 | |
| Next Split | N/A | N/A |
| Last Ticker Change | KMPH | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.28 | |
| EPS Estimate | $1.16 | |
| EPS Est. Change | +150.85% | |
| Revenue | $23.61M | |
| Revenue Estimate | $100.38M | |
| Revenue Est. Change | +325.11% | |
| Current Price | $8.34 | |
| Price Target | - | $23.00 |
| Price Tgt. Change | - | +175.78% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.18 | -$1.30 | -10.08% | |
| -$1.93 | -$2.28 | -18.12% | |
| $1.16 | N/A | +150.85% | |
| $0.62 | N/A | +127.18% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $25.98M | $27.46M | +5.70% | |
| $20.51M | $23.61M | +15.10% | |
| $100.38M | N/A | +325.11% | |
| $144.08M | N/A | +510.20% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -4.79% | |
| Price, 3Y | +81.70% | |
| Market Cap, 1Y | -0.13% | |
| Market Cap, 3Y | +196.15% | |
| Revenue, 1Y | -14.02% | |
| Revenue, 3Y | -17.58% | |
| EPS, 1Y | -75.63% | |
| EPS, 3Y | -7.92% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $8.34 | |
| SMA 200 | $9.15 | |
| SMA 200 vs Price | +9.71% | |
| SMA 50 | $9.09 | |
| SMA 50 vs Price | +8.97% | |
| Beta | 0.65 | |
| ATR | $0.41 | |
| 14-Day RSI | 42.71 | |
| 10-Day Volatility | 45.50% | |
| 1-Year Volatility | 57.15% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $23.61M | |
| EPS | -$2.28 | |
| Gross Profit | $3.57M | |
| Gross Margin | 15.12% | |
| Operating Profit | -$87.00M | |
| Operating Margin | -368.47% | |
| Net Income | -$105.51M | |
| Net Margin | -446.85% | |
| EBITDA | -$80.61M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.52 | |
| 2.53 | ||
| 2.47 | ||
| - | ||
| 5 | ||
| -3.07 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 13.22 | |
| 5.56 | ||
| 3.53 | ||
| -14.08 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $39.67M | |
| $69.50M | ||
| $178.13M | ||
| $86.03M | ||
| $138.46M | ||
| $34.07M | ||
| Total Debt | $60.30M | |
| $420.00K | ||
| $13.08M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $129.12M | ||
| $90.57M | ||
| $20.04M | ||
| $0.00 | ||
| $6.39M | ||
| $0.00 | ||
| $15.37M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$69.67M | ||
| -$22.16M | ||
| $82.11M | ||
| Capex | $0.00 | |
| -$69.67M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Cantor Fitzgerald | → | |
| Canaccord Genuity | → | |
| JMP Securities | → | |
| Cantor Fitzgerald | → | |
| HC Wainwright & Co. | ||
| Cantor Fitzgerald | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| Canaccord Genuity | → | |
| Citizens Capital Markets | → |
Analyst sentiment
Institutional ownership
Screeners with ZVRA
Data Sources & References
- ZVRA Official Website zevra.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1434647/000143464725000011/0001434647-25-000011-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1434647/000143774925007320/0001437749-25-007320-index.htm
- ZVRA Profile on Yahoo Finance finance.yahoo.com/quote/ZVRA
- ZVRA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/zvra
FAQ
What is the ticker symbol for Zevra Therapeutics, Inc.?
The ticker symbol for Zevra Therapeutics, Inc. is NASDAQ:ZVRA
Does Zevra Therapeutics, Inc. pay dividends?
No, Zevra Therapeutics, Inc. does not pay dividends
What sector is Zevra Therapeutics, Inc. in?
Zevra Therapeutics, Inc. is in the Healthcare sector
What industry is Zevra Therapeutics, Inc. in?
Zevra Therapeutics, Inc. is in the Biotechnology industry
What country is Zevra Therapeutics, Inc. based in?
Zevra Therapeutics, Inc. is headquartered in United States
When did Zevra Therapeutics, Inc. go public?
Zevra Therapeutics, Inc. initial public offering (IPO) was on April 16, 2015
Is Zevra Therapeutics, Inc. in the S&P 500?
No, Zevra Therapeutics, Inc. is not included in the S&P 500 index
Is Zevra Therapeutics, Inc. in the NASDAQ 100?
No, Zevra Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Zevra Therapeutics, Inc. in the Dow Jones?
No, Zevra Therapeutics, Inc. is not included in the Dow Jones index
When was Zevra Therapeutics, Inc. last earnings report?
Zevra Therapeutics, Inc.'s most recent earnings report was on November 5, 2025
When does Zevra Therapeutics, Inc. report earnings?
The next expected earnings date for Zevra Therapeutics, Inc. is March 10, 2026